338 related articles for article (PubMed ID: 3610554)
1. Ocular disposition of aminozolamide in the rabbit eye.
Putnam ML; Schoenwald RD; Duffel MW; Barfknecht CF; Segarra TM; Campbell DA
Invest Ophthalmol Vis Sci; 1987 Aug; 28(8):1373-82. PubMed ID: 3610554
[TBL] [Abstract][Full Text] [Related]
2. Characterization of arylamine acetyltransferase in the rabbit eye.
Campbell DA; Schoenwald RD; Duffel MW; Barfknecht CF
Invest Ophthalmol Vis Sci; 1991 Jul; 32(8):2190-200. PubMed ID: 2071333
[TBL] [Abstract][Full Text] [Related]
3. A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion.
Brechue WF; Maren TH
Exp Eye Res; 1993 Jul; 57(1):67-78. PubMed ID: 8405174
[TBL] [Abstract][Full Text] [Related]
4. On the pharmacology of L-645,151: a topically effective ocular hypotensive carbonic anhydrase inhibitor.
Sugrue MF; Gautheron P; Schmitt C; Viader MP; Conquet P; Smith RL; Share NN; Stone CA
J Pharmacol Exp Ther; 1985 Feb; 232(2):534-40. PubMed ID: 3838190
[TBL] [Abstract][Full Text] [Related]
5. Biopharmaceutical explanation for the topical activity of 6-hydroxyethoxy-2-benzothiazolesulfonamide in the rabbit eye.
Lee DY; Schoenwald RD; Barfknecht CF
J Ocul Pharmacol; 1992; 8(3):247-65. PubMed ID: 1453087
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide--a novel topically active carbonic anhydrase inhibitor.
Sharir M; Pierce WM; Chen D; Zimmerman TJ
Exp Eye Res; 1994 Jan; 58(1):107-16. PubMed ID: 8157096
[TBL] [Abstract][Full Text] [Related]
7. L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals.
Sugrue MF; Gautheron P; Mallorga P; Nolan TE; Graham SL; Schwam H; Shepard KL; Smith RL
Br J Pharmacol; 1990 Jan; 99(1):59-64. PubMed ID: 2110013
[TBL] [Abstract][Full Text] [Related]
8. Aminozolamide suspension: the role of the vehicle in a topical carbonic anhydrase inhibitor.
Lewis RA; Schoenwald RD; Barfknecht CF
J Ocul Pharmacol; 1988; 4(3):215-9. PubMed ID: 3198983
[TBL] [Abstract][Full Text] [Related]
9. Site of ocular hydrolysis of a prodrug, dipivefrin, and a comparison of its ocular metabolism with that of the parent compound, epinephrine.
Anderson JA; Davis WL; Wei CP
Invest Ophthalmol Vis Sci; 1980 Jul; 19(7):817-23. PubMed ID: 7390729
[TBL] [Abstract][Full Text] [Related]
10. Ocular distribution studies of the topical carbonic anhydrase inhibitors L-643,799 and L-650,719 and related alkyl prodrugs.
Grove J; Gautheron P; Plazonnet B; Sugrue MF
J Ocul Pharmacol; 1988; 4(4):279-90. PubMed ID: 3246565
[TBL] [Abstract][Full Text] [Related]
11. The ocular penetration of topical forskolin and its effects on intraocular pressure, aqueous flow rate and cyclic AMP level in the rabbit eye.
Matsumoto S; Yamashita T; Araie M; Kametani S; Hosokawa T; Takase M
Jpn J Ophthalmol; 1990; 34(4):428-35. PubMed ID: 1964483
[TBL] [Abstract][Full Text] [Related]
12. Determination of ethoxzolamide in the iris/ciliary body of the rabbit eye by high-performance liquid chromatography: comparison of tissue levels following intravenous and topical administrations.
Eller MG; Schoenwald RD
J Pharm Sci; 1984 Sep; 73(9):1261-4. PubMed ID: 6491947
[TBL] [Abstract][Full Text] [Related]
13. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
Acheampong AA; Shackleton M; Tang-Liu DD
Drug Metab Dispos; 1995 Jul; 23(7):708-12. PubMed ID: 7587958
[TBL] [Abstract][Full Text] [Related]
14. Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist.
Russell KR; Wang DR; Potter DE
Exp Eye Res; 2000 May; 70(5):675-82. PubMed ID: 10870526
[TBL] [Abstract][Full Text] [Related]
15. Ocular penetration and hypotensive activity of the topically applied carbonic anhydrase inhibitor L-645,151.
Bar-Ilan A; Pessah NI; Maren TH
J Ocul Pharmacol; 1986; 2(2):109-20. PubMed ID: 3503100
[TBL] [Abstract][Full Text] [Related]
16. Intraocular production and release of nerve growth factor after iridectomy.
Lambiase A; Bonini S; Manni L; Ghinelli E; Tirassa P; Rama P; Aloe L
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2334-40. PubMed ID: 12091435
[TBL] [Abstract][Full Text] [Related]
17. Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide.
Maren TH; Brechue WF; Bar-Ilan A
Exp Eye Res; 1992 Jul; 55(1):73-9. PubMed ID: 1397133
[TBL] [Abstract][Full Text] [Related]
18. Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine.
Ogidigben M; Chu TC; Potter DE
J Pharmacol Exp Ther; 1993 Nov; 267(2):822-7. PubMed ID: 7902435
[TBL] [Abstract][Full Text] [Related]
19. Penetration into the anterior chamber via the conjunctival/scleral pathway.
Schoenwald RD; Deshpande GS; Rethwisch DG; Barfknecht CF
J Ocul Pharmacol Ther; 1997 Feb; 13(1):41-59. PubMed ID: 9029439
[TBL] [Abstract][Full Text] [Related]
20. Lack of prostaglandin F2 alpha metabolism by human ocular tissues.
Cheng-Bennett A; Poyer J; Weinkam RJ; Woodward DF
Invest Ophthalmol Vis Sci; 1990 Jul; 31(7):1389-93. PubMed ID: 2365570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
